Technology: The DRP® Platform
By using DRP®, we allow the tumor tell us what is most important for drug response.
The DRP® technology is a unique and best-in-class proprietary diagnostic platform. It is built upon a deep systems biology analysis of all transcriptional (RNA) changes in tumor cells in response to a broad range of drug types and refined with actual gene expression data from more than 3,000 patient tumors.
The power of DRP® technology to identify patient responders has been validated in more than 35 cancer clinical trials across numerous indications and drug types.
DRP® technology leverages our sophisticated understanding of the multiple genetic and transcriptional changes that occur in most cancers. The power of this technology comes from the millions of datapoints feeding the proprietary DRP® algorithm and the transcriptional profiling that provides a detailed picture of a patient’s tumor. The DRP® system further refines a tumor response profile through a clinical relevance filter to eliminate unnecessary biomarkers. By remaining agnostic to what influences tumor response to a drug, DRP® enables the identification of unknown biomarkers crucial to drug response or resistance. This is the key to the DRP® platform’s superiority to alternative cancer biomarker approaches.
- High success rates: 80+% predictive accuracy for patient responders
- Efficacy across broad array of drug types (targeted kinase inhibitors, epigenetic inhibitors, chemotherapeutics, DNA repair inhibitors)
- Efficacy across a broad array of solid and liquid tumor types
- Validation in more than 35 clinical trials
- Response signature-specific for each drug
- Strong patent positions: 30+ global drug patents in 75 drugs with 20 years of market exclusivity, and ongoing new patent filings for new DRPs®
The DRP® technology is broadly applicable not only to Allarity’s clinical pipeline, but to a wide range of anti-cancer drugs that are currently approved or are being developed across the industry.
This provides the opportunity to match more drugs to the right patient, improving therapeutic outcomes and avoiding unnecessary treatments, toxicities, and costs — and ushering in a true era of personalized cancer medicine.
Oncology expert Dan Von Hoff, MD, explains the benefits of the DRP® technology.
The video was made when the name of Allarity Therapeutics was still Medical Prognosis Institute (MPI), before it became Oncology Venture and then Allarity.
DRP® companion diagnostics deliver:
Value for the patient
If a cancer patient starts early therapy with an efficacious drug, this may have a beneficial impact on the outcome of his/her treatment. It is valuable for individual patients to receive guidance on whether a specific drug is likely to have an impact on their cancer, avoiding therapies that may not be likely to be efficacious.
Value for treatment payors
DRP® companion diagnostics can help find the right drug for the right patient earlier in the treatment cycle, which leads to better health outcomes and substantial health economics benefits. Conversely, DRP® companion diagnostics can identify therapies that are less likely to work, avoiding unnecessary deployment of costs and health system resources.
Value for drug development partners
Less than 5% of cancer drugs in clinical development are expected to lead to marketing approval. By partnering with Allarity Therapeutics in the development of a drug, and utilizing the DRP® Platform to identify subjects who are more likely to respond to the drug candidate, clinical development can be more efficient, reducing the risk of failure and wasted time and costs to get to market.